Home Alzheimer’s Disease TKI Combination Shows Promise Against MET Resistance in EGFR+, MET-Amplified NSCLC

TKI Combination Shows Promise Against MET Resistance in EGFR+, MET-Amplified NSCLC

Savolitinib (AZD6094) demonstrated the ability to overcome MET resistance in patients with EGFR-mutant, MET-amplified or -overexpressed non–small cell lung cancer (NSCLC) when combined with osimertinib (Tagrisso), and these benefits extended to those with disease that had previously progressed on a prior EGFR tyrosine kinase inhibitor (TKI). These results from the final analysis of the expansion cohorts of the phase 1b TATTON study (NCT02143466) were presented virtually at the 2020 World Conference on Lung Cancer Singapore.1

In part B of the trial, which had 3 cohorts, results showed that the overall response rate (ORR) was 33% (95% CI, 22%-46%) in cohort 1, in which patients had received a prior third-generation EGFR TKI. Cohort 2, in which patients did not have a prior third-generation EGFR TKI and were T790M-negative, showed an ORR of 65% (95% CI, 50%-78%).

In cohort 3, where…

Continue Reading to the Source

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

Toni Choueiri, MD, on What Multidisciplinary Stakeholders Should Know About CheckMate 9ER

Results from the phase 3 CheckMate 9ER trial (NCT03141177) presented at the American Society of Clinical Oncology (ASCO) 2021 Genitourinary Cancer Symposium revealed that...

Robert J. Motzer, MD, on the Rationale for the Phase 3 CheckMate 9ER Trial in Advanced RCC

Compared with sunitinib (Sutent), combination treatment with nivolumab and cabozantinib demonstrated improved efficacy and prolonged survival among patients with previously treated advanced renal cell...

PHERGain II Trial Launched to Examine Chemotherapy-Free Treatment for Patients With HER2+ Breast Cancer

A clinical trial to support the use of a chemotherapy-free therapeutic approach has been launched and will aim to demonstrate that this approach is...

FDA Grants Breakthrough Therapy Designation to Tipifarnib for Treatment of HRAS-Mutant HNSCC

The FDA has granted breakthrough therapy designation to the investigational drug tipifarnib for the treatment of patients with recurrent or metastatic HRAS-mutant head and...

Recent Comments